tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

SNY Stock Latest News

Sanofi’s Tolebrutinib Study: A Potential Game-Changer for Multiple Sclerosis Treatment
Company AnnouncementsSanofi’s Tolebrutinib Study: A Potential Game-Changer for Multiple Sclerosis Treatment
3d ago
SNY
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
3d ago
SNY
REGN
Sanofi’s Observational Study on Teplizumab: Implications for Type 1 Diabetes Treatment
PremiumCompany Announcements
Sanofi’s Observational Study on Teplizumab: Implications for Type 1 Diabetes Treatment
3d ago
SNY
Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis Treatment
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Frexalimab: A Potential Game-Changer for Multiple Sclerosis Treatment
3d ago
SNY
Sanofi’s Phase 3 Study on Riliprubart: A Potential Game-Changer for CIDP Treatment?
PremiumCompany Announcements
Sanofi’s Phase 3 Study on Riliprubart: A Potential Game-Changer for CIDP Treatment?
4d ago
SNY
Sanofi’s New Phase 2 Study: A Potential Game-Changer in Multiple Myeloma Treatment
PremiumCompany AnnouncementsSanofi’s New Phase 2 Study: A Potential Game-Changer in Multiple Myeloma Treatment
4d ago
SNY
Sanofi’s TZIELD® Study: Long-term Safety Insights for Type 1 Diabetes
Premium
Company Announcements
Sanofi’s TZIELD® Study: Long-term Safety Insights for Type 1 Diabetes
4d ago
SNY
Sanofi’s Gene Therapy Trial for PKU: A Market Game Changer?
Premium
Company Announcements
Sanofi’s Gene Therapy Trial for PKU: A Market Game Changer?
4d ago
SNY
Sanofi’s Dupilumab Study: A Game Changer for Atopic Dermatitis Treatment?
PremiumCompany Announcements
Sanofi’s Dupilumab Study: A Game Changer for Atopic Dermatitis Treatment?
4d ago
SNY
Regeneron and Sanofi’s Expanded Access Program for Dupilumab: A Potential Market Mover
PremiumCompany Announcements
Regeneron and Sanofi’s Expanded Access Program for Dupilumab: A Potential Market Mover
4d ago
SNY
REGN
Sanofi’s Innovative Approach in RRMM Treatment: A Closer Look at the Latest Clinical Study
PremiumCompany Announcements
Sanofi’s Innovative Approach in RRMM Treatment: A Closer Look at the Latest Clinical Study
4d ago
SNY
Sanofi’s Promising Phase 2 Study on SAR441566 for Ulcerative Colitis
PremiumCompany Announcements
Sanofi’s Promising Phase 2 Study on SAR441566 for Ulcerative Colitis
4d ago
SNY
Sanofi’s Teplizumab Study: A New Hope for Japanese Type 1 Diabetes Patients
PremiumCompany AnnouncementsSanofi’s Teplizumab Study: A New Hope for Japanese Type 1 Diabetes Patients
4d ago
SNY
Kymera Therapeutics assumed with an Overweight at Morgan Stanley
Premium
The Fly
Kymera Therapeutics assumed with an Overweight at Morgan Stanley
5d ago
SNY
GILD
Sanofi price target lowered to EUR 115 from EUR 125 at Barclays
Premium
The Fly
Sanofi price target lowered to EUR 115 from EUR 125 at Barclays
5d ago
SNY
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
PremiumCompany Announcements
Regeneron and Sanofi’s Dupilumab Study: A Potential Game-Changer for Pediatric Asthma
5d ago
SNY
REGN
Sanofi’s Phase 3 MS Study: Tolebrutinib vs. Teriflunomide
PremiumCompany Announcements
Sanofi’s Phase 3 MS Study: Tolebrutinib vs. Teriflunomide
5d ago
SNY
Sanofi’s Tolebrutinib Study Completion: A Potential Game-Changer for NRSPMS Treatment
PremiumCompany Announcements
Sanofi’s Tolebrutinib Study Completion: A Potential Game-Changer for NRSPMS Treatment
5d ago
SNY
Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
PremiumCompany Announcements
Sanofi’s Frexalimab Study: A Potential Game-Changer for Multiple Sclerosis Treatment
5d ago
SNY
Sanofi’s Observational Study on Teplizumab: Real-World Insights for Type 1 Diabetes
PremiumCompany AnnouncementsSanofi’s Observational Study on Teplizumab: Real-World Insights for Type 1 Diabetes
5d ago
SNY
Sanofi’s Tolebrutinib Study: A New Hope for MS Treatment?
Premium
Company Announcements
Sanofi’s Tolebrutinib Study: A New Hope for MS Treatment?
5d ago
SNY
Sanofi’s Riliprubart Gains Orphan Drug Status in US and Japan
Premium
Company Announcements
Sanofi’s Riliprubart Gains Orphan Drug Status in US and Japan
6d ago
6K
SNY

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >